-65.8%
RBLX vs MRNA
+485.7%
-551.5%
-74.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.4% | +5.4% | -4.0% | +1.2% |
| 7D | +5.1% | -1.1% | +6.1% | +5.1% |
| 30D | +28.0% | +126.1% | -98.1% | +20.0% |
| 3M | +4.6% | +190.0% | -185.4% | -5.1% |
| 6M | -24.7% | +157.2% | -181.9% | -31.2% |
| YTD | -43.8% | +388.2% | -432.0% | -49.4% |
| 1Y | -65.8% | +467.0% | -532.8% | -67.9% |
| All | -65.8% | +485.7% | -551.5% | -67.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling